非小细胞肺癌获得性Thr790Met突变患者接受奥希替尼治疗的转归:一项基因组学研究
该研究基于AURA试验单中心数据,分析53例既往EGFR-TKI耐药且检出EGFR活化突变及获得性Thr790Met突变的非小细胞肺癌患者,口服奥希替尼20-240 mg/日。进展后血浆Thr790Met检出率30%,耐药机制呈异质性。
要点
- 进展后血浆Thr790Met检出率30%,可见Cys797Ser等获得性突变。
- 进展后肿瘤样本可见鳞癌及小细胞癌转化,提示耐药机制异质。
核心结论
- 接受奥希替尼治疗的患者出现异质性耐药机制,不同耐药机制可能影响未来临床试验策略。
研究设计与样本
- AURA研究单中心入组患者中筛选既往EGFR-TKI耐药、肿瘤组织或血浆可检出EGFR活化突变及获得性Thr790Met突变者。
- 共53例符合分析条件,口服奥希替尼20-240 mg/日直至疾病进展或出现不可耐受副作用。
- 每6周采集血浆样本,研究入组时行肿瘤组织活检,疾病进展后活检为可选。
主要发现
- 40例有进展后血浆样本,其中12例(30%)检出Thr790Met突变,4例同时检出Cys797Ser突变。
关键数值与推荐
- 22例进展后肿瘤样本中检出1例鳞状细胞转化和2例小细胞转化。
- 18例样本中9例(50%)检出Thr790Met,12例中2例(17%)检出Cys797Ser。
- 10例中5例(50%)检出cMET扩增,13例中1例(8%)检出BRAF突变,13例中1例(8%)检出KRAS突变。
临床怎么用
- 对奥希替尼治疗进展的Thr790Met突变NSCLC患者,应重新活检(组织或血浆)评估耐药机制。
- 耐药机制异质性提示需根据进展后分子特征个体化选择后续治疗策略。
局限性
- 研究为单中心分析,样本量有限(53例可分析)。
- 进展后肿瘤组织活检为可选,部分分子检测样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Osimertinib is approved for the treatment of non-small-cell lung cancer in patients who develop the EGFR Thr790Met mutation after treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs). We assessed outcomes in patients with non-small-cell lung cancer and the EGFR Thr790Met mutation who were treated with osimertinib, a third-generation EGFR TKI, after previous treatment failure with one or more other EGFR TKIs. METHODS: Eligible patients had been enrolled at one centre in the AURA study, had shown resistance to a previous EGFR TKI, and had EGFR-activating mutations and acquired Thr790Met mutation detectable in tumour tissue or plasma. Patients took 20-240 mg osimertinib per day until disease progression or development of intolerable side-effects. Plasma samples were collected every 6 weeks and tumour tissue biopsy was done at study entry and was optional after disease progression. We tested samples for resistance mechanisms, including EGFR-activating, Thr790Met, and Cys797Ser mutations, and assessed associations with overall survival, progression-free survival, and survival after disease progression. FINDINGS: Of 71 patients enrolled in AURA, 53 were eligible for this analysis. Median progression-free survival was 11·1 months (95% CI 8·4-13·9) and overall survival was 16·9 months (11·7-29·1). 47 patients had disease progression. Median overall survival after osimertinib progression was 5·4 months (95% CI 4·1-10·0). Plasma samples were available for 40 patients after disease progression. 12 (30%) of these had the Thr790Met mutation (four of whom also had Cys797Ser mutations). Patients without detectable EGFR-activating mutations in plasma before treatment had the best overall and post-progression survival (22·4 months, 95% CI 15·6-not reached, and 10·8 months, 7·2-not reached, respectively). Loss of the Thr790Met mutation but presence of EGFR-activating mutations in plasma were associated with the shortest progression-free survival (median 2·6 months, 95% CI 1·3-not reached). In 22 post-progression tumour samples, we found one squamous cell and two small-cell transformations. We detected Thr790Met in nine (50%) of 18 samples, Cys797Ser in two (17%) of 12, cMET amplification in five (50%) of ten, BRAF mutation in one (8%) of 13, and KRAS mutation in one (8%) of 13. INTERPRETATION: Heterogeneous resistance mechanisms developed in patients receiving osimertinib. Differences in resistance mechanisms might dictate future development strategies for osimertinib in clinical trials. FUNDING: AstraZeneca, Taiwan Ministry of Science and Technology.
引用
- Lin CC, Shih JY, Yu CJ, et al. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. Lancet Respir Med. 2017. PMID: 29249325. doi:10.1016/S2213-2600(17)30480-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。